<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155726</url>
  </required_header>
  <id_info>
    <org_study_id>P-371-C-101</org_study_id>
    <nct_id>NCT01155726</nct_id>
  </id_info>
  <brief_title>The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies</brief_title>
  <acronym>ARGON</acronym>
  <official_title>The Effect of Masking on Subjective Results During Daily Disposable Contact Lens Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the effect of masking on subjective ratings for two
      daily disposable contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Subjective Comfort</measure>
    <time_frame>Insertion, 4 hours, 8 hours each: Day 1, Day 2, and Day 3</time_frame>
    <description>Participants were asked, &quot;How would you rate your comfort with your study lenses?&quot; and indicated their response by marking a continuum line ranging from 0=very poor comfort to 100=excellent comfort. Subjective comfort was collected at three time points (insertion, 4 hours, 8 hours) for 3 days, and the comfort ratings were averaged together.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Myopia</condition>
  <condition>Hyperopia</condition>
  <arm_group>
    <arm_group_label>Nelfilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nelfilcon A, Masked, Partially Masked</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nelfilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etafilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (unmasked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etafilcon A, Masked, Partially Masked</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etafilcon A worn in adaptation phase (bilaterally, 30 days). Period 1: 1DAVM and DACP (masked) worn contralaterally in random assignment for 3 days. Period 2: 1DAVM and DACP (partially masked) worn contralaterally, same assignment, 3 days. All products worn in a daily wear, daily disposable mode.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nelfilcon A contact lens</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.</description>
    <arm_group_label>Nelfilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Nelfilcon A, Masked, Partially Masked</arm_group_label>
    <other_name>Focus DAILIES®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nelfilcon A contact lens with comfort additive (DACP), unmasked</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.</description>
    <arm_group_label>Nelfilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Unmasked</arm_group_label>
    <other_name>DAILIES® AquaComfort Plus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nelfilcon A contact lens with comfort additive (DACP), masked</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.</description>
    <arm_group_label>Nelfilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Nelfilcon A, Masked, Partially Masked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Partially Masked</arm_group_label>
    <other_name>DAILIES® AquaComfort Plus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Nelfilcon A contact lens with comfort additive (DACP), partially masked</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.</description>
    <arm_group_label>Nelfilcon A, Masked, Partially Masked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Partially Masked</arm_group_label>
    <other_name>DAILIES® AquaComfort Plus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etafilcon A contact lens</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.</description>
    <arm_group_label>Etafilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Partially Masked</arm_group_label>
    <other_name>1-DAY ACUVUE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etafilcon A contact lens with comfort additive (1DAVM), unmasked</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.</description>
    <arm_group_label>Nelfilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Unmasked</arm_group_label>
    <other_name>1-DAY ACUVUE® MOIST®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etafilcon A contact lens with comfort additive (1DAVM), masked</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.</description>
    <arm_group_label>Nelfilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Nelfilcon A, Masked, Partially Masked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Unmasked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Partially Masked</arm_group_label>
    <other_name>1-DAY ACUVUE® MOIST®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Etafilcon A contact lens with comfort additive (1DAVM), partially masked</intervention_name>
    <description>Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.</description>
    <arm_group_label>Nelfilcon A, Masked, Partially Masked</arm_group_label>
    <arm_group_label>Etafilcon A, Masked, Partially Masked</arm_group_label>
    <other_name>1-DAY ACUVUE® MOIST®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  17 years of age or older.

          -  Ocular exam within 2 years.

          -  Currently wearing soft contact lenses on a daily wear basis.

          -  Contact lens prescription between +6.00D and -10.00D.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any ocular disease.

          -  Use of systemic or ocular medications that may affect ocular health.

          -  Unable to achieve an acceptable fit with the study lenses.

          -  Anisometropia &gt;1.00D or astigmatism &gt;0.75D.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre for Contact Lens Research: University of Waterloo</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 3G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <results_first_submitted>February 15, 2012</results_first_submitted>
  <results_first_submitted_qc>April 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 15, 2012</results_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>134 participants were recruited and enrolled at 1 study center located in Canada. A 24-hour washout period of no lens wear preceded the 30-day adaptation phase.</recruitment_details>
      <pre_assignment_details>18 participants were enrolled but not dispensed--i.e., discontinued prior to the 30-day adaptation phase. 116 participants started the adaptation phase, and baseline characteristics are presented for this group. 2 discontinued during the adaptation phase and 15 discontinued between adaptation and Period 1 dispense. 99 were dispensed into Period 1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Nelfilcon A, Masked, Unmasked</title>
          <description>Nelfilcon A in adaptation phase. 1DAVM and DACP (contralateral wear, masked) in Period 1. 1DAVM and DACP (contralateral wear, unmasked) in Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Nelfilcon A, Masked, Partially Masked</title>
          <description>Nelfilcon A in adaptation phase. 1DAVM and DACP (contralateral wear, masked) in Period 1. 1DAVM and DACP (contralateral wear, partially masked) in Period 2.</description>
        </group>
        <group group_id="P3">
          <title>Etafilcon A, Masked, Unmasked</title>
          <description>Etafilcon A in adaptation phase. 1DAVM and DACP (contralateral wear, masked) in Period 1. 1DAVM and DACP (contralateral wear, unmasked) in Period 2.</description>
        </group>
        <group group_id="P4">
          <title>Etafilcon A, Masked, Partially Masked</title>
          <description>Etafilcon A in adaptation phase. 1DAVM and DACP (contralateral wear, masked) in Period 1. 1DAVM and DACP (contralateral wear, partially masked) in Period 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1, 3 Days (Masked)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inconvenience</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2, 3 Days (Unmask) or (Partial)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>This reporting group includes all enrolled and dispensed participants.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Subjective Comfort</title>
        <description>Participants were asked, &quot;How would you rate your comfort with your study lenses?&quot; and indicated their response by marking a continuum line ranging from 0=very poor comfort to 100=excellent comfort. Subjective comfort was collected at three time points (insertion, 4 hours, 8 hours) for 3 days, and the comfort ratings were averaged together.</description>
        <time_frame>Insertion, 4 hours, 8 hours each: Day 1, Day 2, and Day 3</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Nelfilcon A, Pd 1 Masked (1DAVM), Pd 2 Unmasked</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O2">
            <title>Nelfilcon A, Pd 1 Masked (DACP), Pd 2 Unmasked</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O3">
            <title>Etafilcon A, Pd 1 Masked (1DAVM), Pd 2 Unmasked</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O4">
            <title>Etafilcon A, Pd 1 Masked (DACP), Pd 2 Unmasked</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O5">
            <title>Nelfilcon A, Pd 1 Masked, Pd 2 Unmasked (1DAVM)</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O6">
            <title>Nelfilcon A, Pd 1 Masked, Pd 2 Unmasked (DACP)</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O7">
            <title>Etafilcon A, Pd 1 Masked, Pd 2 Unmasked (1DAVM)</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O8">
            <title>Etafilcon A, Pd 1 Masked, Pd 2 Unmasked (DACP)</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 unmasked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O9">
            <title>Nelfilcon A, Pd 1 Masked (1DAVM), Pd 2 Partial</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O10">
            <title>Nelfilcon A, Pd 1 Masked (DACP), Pd 2 Partial</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O11">
            <title>Etafilcon A, Pd 1 Masked (1DAVM), Pd 2 Partial</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O12">
            <title>Etafilcon A, Pd 1 Masked (DACP), Pd 2 Partial</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O13">
            <title>Nelfilcon A, Pd 1 Masked, Pd 2 Partial (1DAVM)</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O14">
            <title>Nelfilcon A, Pd 1 Masked, Pd 2 Partial (DACP)</title>
            <description>Nelfilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O15">
            <title>Etafilcon A, Pd 1 Masked, Pd 2 Partial (1DAVM)</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
          <group group_id="O16">
            <title>Etafilcon A, Pd 1 Masked, Pd 2 Partial (DACP)</title>
            <description>Etafilcon A (adaptation phase), followed by Period 1 masked, Period 2 partial masked. Contralateral wear reported by product/eye.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Subjective Comfort</title>
          <description>Participants were asked, &quot;How would you rate your comfort with your study lenses?&quot; and indicated their response by marking a continuum line ranging from 0=very poor comfort to 100=excellent comfort. Subjective comfort was collected at three time points (insertion, 4 hours, 8 hours) for 3 days, and the comfort ratings were averaged together.</description>
          <population>Per protocol</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="28"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="28"/>
                <count group_id="O8" value="28"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="25"/>
                <count group_id="O12" value="25"/>
                <count group_id="O13" value="20"/>
                <count group_id="O14" value="20"/>
                <count group_id="O15" value="25"/>
                <count group_id="O16" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.1" spread="5.9"/>
                    <measurement group_id="O2" value="92.8" spread="6.5"/>
                    <measurement group_id="O3" value="94.1" spread="5.6"/>
                    <measurement group_id="O4" value="91.8" spread="6.4"/>
                    <measurement group_id="O5" value="93.7" spread="6.0"/>
                    <measurement group_id="O6" value="93.3" spread="5.7"/>
                    <measurement group_id="O7" value="95.2" spread="5.8"/>
                    <measurement group_id="O8" value="93.7" spread="6.6"/>
                    <measurement group_id="O9" value="93.4" spread="6.9"/>
                    <measurement group_id="O10" value="93.4" spread="7.1"/>
                    <measurement group_id="O11" value="93.6" spread="5.1"/>
                    <measurement group_id="O12" value="92.2" spread="5.6"/>
                    <measurement group_id="O13" value="92.3" spread="7.0"/>
                    <measurement group_id="O14" value="93.1" spread="7.0"/>
                    <measurement group_id="O15" value="93.5" spread="6.7"/>
                    <measurement group_id="O16" value="92.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Unmasked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Unmasked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Unmasked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>2.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <groups_desc>Unmasked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>Partial masked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O10</group_id>
              <group_id>O14</group_id>
            </group_id_list>
            <groups_desc>Partial masked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>Partial masked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O12</group_id>
              <group_id>O16</group_id>
            </group_id_list>
            <groups_desc>Partial masked minus masked</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study: 03 May 2010 through 01 February 2011.</time_frame>
      <desc>This reporting group includes all enrolled and exposed participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nelfilcon A</title>
          <description>Nelfilcon A contact lenses</description>
        </group>
        <group group_id="E2">
          <title>Etafilcon A</title>
          <description>Etafilcon A contact lenses</description>
        </group>
        <group group_id="E3">
          <title>1DAVM</title>
          <description>Etafilcon A with comfort additive contact lenses</description>
        </group>
        <group group_id="E4">
          <title>DACP</title>
          <description>Nelfilcon A with comfort additive contact lenses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Alcon Research</organization>
      <phone>1-800-241-7629</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

